
|Articles|January 15, 2004
Ruboxistaurin reduces visual loss in diabetic retinopathy
New Orleans-Ruboxistaurin mesylate, a protein kinase C (PKC) beta inhibitor, reduces loss of vision in patients with moderate-ly severe to very severe nonproliferativediabetic retinopathy, researchers reported at the American Diabetes Association meet-ing here.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Nanoscope Therapeutics releases positive long-term safety results from EXTEND study
2
Avisi Technologies releases positive 12-month data from VITA Trial
3
Ocular Therapeutix reaches target enrollment of 555 patients in SOL-R trial
4
Selecting Anti-VEGF Therapies in Retinal Vascular Disease Management
5


















































.png)


